8-K: Matinas BioPharma Faces NYSE American Delisting Warning

Matinas BioPharma Holdings, Inc. received a notice from the NYSE American for failing to meet continued listing standards, with a plan in place to regain compliance by October 2, 2027.

Summary

• Matinas BioPharma Holdings, Inc. received a notice from the NYSE American on August 31, 2026, indicating non-compliance with continued listing standards.
• The company's stockholders equity was reported at $1.8 million as of June 30, 2026, falling below the $2.0 million requirement for companies with recent losses.
• This non-compliance stems from losses in the company's five most recent fiscal years and also violates standards related to $4.0 million and $6.0 million in stockholders equity.
• A plan submitted on May 4, 2026, to regain compliance was accepted by the NYSE American, with a deadline of October 2, 2027, to achieve compliance.
• Failure to meet compliance by the deadline or demonstrate consistent progress could lead to delisting proceedings.
• The notice does not immediately affect the trading of the company's common stock on the NYSE American, which will continue under the symbol MTNB with a '.BC' indicator.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's continued non-compliance with NYSE American listing standards, despite a plan to regain compliance.

Positives

• The NYSE American has accepted the company's plan to regain compliance with continued listing standards.
• The company has until October 2, 2027, to demonstrate compliance.
• The notice has no immediate impact on the listing or trading of the company's shares on the NYSE American.
• The company's ongoing business operations and SEC reporting requirements are unaffected by the notice.

Negatives

• The company is not in compliance with NYSE American continued listing standards related to minimum stockholders equity ($2.0 million, $4.0 million, and $6.0 million thresholds).
• Stockholders equity was $1.8 million as of June 30, 2026, below the $2.0 million minimum.
• The company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
• The company will continue to be listed with a '.BC' indicator, signifying non-compliance.

Risks

• If Matinas BioPharma does not regain compliance with all stockholders equity standards by October 2, 2027, or does not make progress consistent with its plan, the NYSE American will initiate delisting proceedings.
• The company may appeal a staff delisting determination, but this process is subject to NYSE American procedures.
• The '.BC' indicator will remain on the company's ticker symbol until compliance is regained, potentially affecting investor perception.

Future Outlook

The company has a plan and a deadline of October 2, 2027, to regain compliance with NYSE American continued listing standards. Failure to do so could result in delisting proceedings.

Management Comments

• The Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American.
• The Company will continue to be included in the list of NYSE American noncompliant issuers, and the common stock will continue to trade under the symbol MTNB.
• The .BC indicator will continue to be disseminated with the Company's ticker symbol.
• The .BC indicator will be removed when the Company has regained compliance with all applicable continued listing standards.
• The Notice does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.

Industry Context

StockSavvy.ai notes that non-compliance with exchange listing standards, particularly concerning financial health metrics like stockholders equity, is a common challenge for early-stage or development-stage biopharmaceutical companies. Such notices often signal financial strain or a prolonged period of unprofitability, requiring strategic action to rectify.

Comparison to Industry Standards

• The filing indicates Matinas BioPharma's stockholders equity of $1.8 million as of June 30, 2026, is below the NYSE American's minimum requirement of $2.0 million for continued listing under Section 1003(a)(i).
• The company has also failed to meet the $4.0 million and $6.0 million stockholders equity requirements under Sections 1003(a)(ii) and 1003(a)(iii), respectively, due to losses in its five most recent fiscal years.
• Industry peers in the biopharmaceutical sector often face similar challenges with listing requirements if they experience significant R&D expenses and extended periods without revenue generation, necessitating careful financial management and strategic planning to maintain exchange compliance.

Stakeholder Impact

• Shareholders: Continued listing on NYSE American is maintained for now, but the risk of delisting poses a significant threat to liquidity and share value if compliance is not achieved.
• Creditors: The company's financial health, indicated by its equity position and ongoing losses, could impact its ability to meet debt obligations.
• Employees: Potential delisting could create uncertainty regarding the company's long-term viability and job security.

Next Steps

• Matinas BioPharma must regain compliance with all stockholders equity standards by October 2, 2027.
• The company must demonstrate progress consistent with its submitted plan during the plan period.
• If compliance is not achieved, the NYSE American will initiate delisting proceedings.
• The company may appeal any staff delisting determination.

Key Dates

Recommendation

The company is facing significant listing compliance issues, which is a major negative. However, it has a plan and a deadline to rectify the situation, and its core business operations are not immediately impacted. A 'hold' recommendation reflects the uncertainty and risk associated with regaining compliance, balanced against the potential for recovery if the plan is successful.

Keywords

NYSE American, Listing Standards, Stockholders Equity, Delisting, Compliance Plan, Biopharmaceutical, Form 8-K